

PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES
October 8, 2013

The meeting was called to order at approximately 1:33 p.m. on Tuesday, October 8, 2013.

Committee members present: Melissa Bowlby, PA-C; James Zedaker, PA-C; Margaret Huwer, Pharm.D.; Anita Steinbergh, D.O.; Theresa Hoffmann, Pharm. D.; Robert Flora, M.D.; and Eric Luckage.

Staff members present: Sallie Debolt, and Cathy Hacker

I. Review of the September 10, 2013 minutes.

Ms. Bowlby began the meeting by requesting the approval of the minutes.

Ms. Hoffmann and Ms. Huwer requested that two small changes be made to the minutes. Ms. Hoffmann requested that the last sentence in the Formulary review section of the minutes state that she would be submitting more medications that have been FDA approved in the coming month to consider.

Ms. Huwer requested that her question regarding the Board's requirement of 2 years of experience for special services read more like an inquiry than a challenge.

Dr. Steinbergh moved to approve the minutes as amended from the September 10, 2013 PAPC meeting. Mr. Zedaker seconded the motion. All members voted aye. The motion carried.

II. Formulary Review

The committee considered the following medications and made these changes to the formulary:

Bydureon: currently in CTP may prescribe category, no change.

Voraxaze: currently in PI category, no change.

Inlyta: currently in CTP may not prescribe category, no change.

Picato: currently in CTP may prescribe category, no change.

Kalydeco: currently in CTP may not prescribe category, no change.

Mitosol: currently in CTP may not prescribe category, no change.

Zioptan: currently in PI category, no change.

Sklice: currently in CTP may prescribe category, no change.

Surfaxin: was added to the formulary as a surfactant in the PI category, with neonatology management.

Binosto: currently in CTP may prescribe category, no change

Omontys: currently in PI category, no change.

Candidas: currently in PI category, no change.

Regranex: currently in CTP may prescribe category, no change.

Amyvid: currently in CTP may prescribe category, no change.

Stendra: currently in CTP may prescribe category, no change.

Absorica: currently in CTP may not prescribe category, no change.

Elelyso: currently in PI category, no change.

Dymista: currently in CTP may prescribe category, no change.

Belviq: currently in the CTP may not due to the Board's weight loss rules. No change.

Perjeta: currently in CTP may not prescribe category, no change.

Myrbetriq: currently in CTP may prescribe category, no change.

Dr. Steinbergh moved to approve the formulary as amended. Dr. Flora seconded the motion. All members voted aye. The motion carried.

III. Review Special Services applications

The committee discussed the application from **Downtown Dermatology** that is requesting approval of injection of Botox A for hyperhidrosis and cosmetic purposes that are FDA approved.

The committee felt that this application showed poor patient prioritization as they state that they are seeing 50 patients a day and that patients with possible melanomas would have to wait months to see a physician if the PA could not perform these Botox injections. The committee would like the utilization of the PA performing these injections to be better defined such as prioritize patients that have skin lesions to be seen before patients that are requesting cosmetic services.

They requested that the areas to be injected for hyperhidrosis be defined and that these applications be separated into two applications. The physician(s) need to submit one application for injecting Botox for hyperhidrosis and a separate application for injecting Botox for cosmetic purposes.

The committee requested that this application be separated into two applications. They must submit one application for injecting Botox for cosmetic purposes and one for injecting Botox for hyperhidrosis.

Dr. Steinbergh moved to table this application until they resubmit it as two separate applications. Mr. Luckage seconded the motion. All members voted aye. The motion carried.

The committee discussed the applications from Mercy Defiance Clinic that is requesting approval of sub-acromial bursa injections and intra-articular shoulder injections.

The committee recognized that these types of applications had been approved in the past. However, they requested that the reference to a specific PA be removed and that the levels of supervision reflect 0% direct supervision, 100% onsite supervision and 0% offsite supervision.

Dr. Steinbergh moved to approve these applications when amended. Mr. Zedaker seconded the motion all members voted aye. The motion carried.

IV. New Business matters

No new matters were discussed

The Physician Assistant Policy Committee meeting was adjourned by Ms. Bowlby at approximately 2:14 p.m. on Tuesday, October 8, 2013.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on October 8, 2013.

Melissa Bowlby, PA-C
Chair, PAPC

Copies of documents and/or materials referenced in the minutes of the Physician Assistant Policy Committee meeting are available at the Board offices.